The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 03, 2025

Filed:

Feb. 11, 2018
Applicant:

Shenzhen Linglan Bio-pharmaceutical Technology Co., Ltd, Shenzhen, CN;

Inventors:

Yongkai Cao, Shenzhen, CN;

Zili Zhang, Shenzhen, CN;

Seung Hoon Cheon, Shenzhen, CN;

Kyeong Man Kim, Shenzhen, CN;

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 241/04 (2006.01); A61P 15/10 (2006.01); A61P 25/00 (2006.01); A61P 25/14 (2006.01); A61P 25/16 (2006.01); A61P 25/18 (2006.01); A61P 25/30 (2006.01); C07D 401/06 (2006.01); C07D 401/12 (2006.01); C07D 403/06 (2006.01); C07D 403/12 (2006.01); C07D 405/12 (2006.01); C07D 409/12 (2006.01); C07D 413/12 (2006.01); C07D 417/12 (2006.01);
U.S. Cl.
CPC ...
C07D 241/04 (2013.01); A61P 25/16 (2018.01); C07D 401/12 (2013.01); C07D 403/06 (2013.01); C07D 403/12 (2013.01); C07D 405/12 (2013.01); C07D 409/12 (2013.01); C07D 413/12 (2013.01); C07D 417/12 (2013.01);
Abstract

The present invention provides a novel ligand for the dopamine D3 receptor and a preparation method therefor. The compound, and a pharmaceutically acceptable salt and a pharmaceutical composition or a pharmaceutical preparation thereof are used for the treatment and prevention of schizophrenia, neurodegenerative diseases, particularly Parkinson's disease, drug dependence, drug addiction, anxiety, depression, etc. The novel ligand of the dopamine D3 receptor features a high affinity, a high specificity, and a high functional selectivity. The compound and the pharmaceutically acceptable salt and the pharmaceutical composition or the pharmaceutical preparation thereof can be used to study the distribution and function of dopamine D2 subtype receptors and mechanism of diseases associated with dysfunction of dopamine D2-like receptors, and can also be used for the disease modification of hyperprolactinemia, extrapyramidal symptoms, and levodopa-associated movement disorder or dyskinesia.


Find Patent Forward Citations

Loading…